Fig. 3.

Clinically, ADAM22 expression is associated with relapse and brain metastasis and may be a suitable candidate for targeted therapy. a Kaplan–Meier estimates of disease-free survival according to ADAM22 in all (n = 843 patients) (log rank, Pr > χ² = 0.0208). b Kaplan–Meier estimates of disease-free survival according to ADAM22 in ER-positive breast cancer patients (n = 670 patients) (log rank, Pr > χ² = 0.0432). c Immunohistochemical ADAM22 staining in 6 ER-positive endocrine-treated primary breast tumours and matched metastatic tissue. ADAM22 expression was maintained or elevated on metastasis. Scale bar, 50 μm. d Immunohistochemical ADAM22 staining in normal healthy tissues. Scale bar, 20 μm for brain and 50 μm for all other organs